ArticleEuropean urology2013
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
Article in European urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Effects of resistance exercise in prostate cancer patients: a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Pooled it
- Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.Journal of diabetes investigation · 2016Pooled it
- Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors.The Prostate · 2025Article
- Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer.Cardio-oncology (London, England) · 2025Article
- Article
- Extra-Gonadal and Non-Canonical Effects of FSH in Males.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer.Cancers · 2023Review
- Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.International journal of cancer · 2022Article
- Management of Biochemical Recurrence of Prostate Cancer After Curative Treatment: A Focus on Older Patients.Drugs & aging · 2022Review
- Article
- Article
- The Effect of Testosterone on Cardiovascular Disease and Cardiovascular Risk Factors in Men: A Review of Clinical and Preclinical Data.CJC open · 2021Review
- Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.JAMA network open · 2021Article
- Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.The Prostate · 2020Review
- Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer.BMC cancer · 2020Article
- New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk.World journal of urology · 2019Article
- Landmarks in prostate cancer.Nature reviews. Urology · 2018Review
- Cardiovascular Care Among Cancer Survivors in the United States.JNCI cancer spectrum · 2018Article
- Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.British journal of cancer · 2017Article
- The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.Prostate cancer and prostatic diseases · 2017Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAndrogen-deprivation therapy (ADT) for prostate cancer (PCa) may be associated with cardiovascular disease and diabetes. Some data suggest that men with certain conditions may be more susceptible to developing cardiovascular disease than others.
objectiveTo assess whether the risk of myocardial infarction (MI) or diabetes during ADT is modified by specific baseline comorbidities. DESIGN, SETTING, AND
participantsWe conducted a population-based observational study of 185 106 US men ≥66 yr of age diagnosed with local/regional PCa from 1992 to 2007. We assessed comorbidities monthly over the follow-up period. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazards models with time-varying variables assessing incident diabetes or MI. RESULTS AND LIMITATIONS: A total of 49.9% of the men received ADT during follow-up. Among men with no comorbidities, ADT was associated with an increase in the adjusted hazard of MI (adjusted hazard ratio [AHR]: 1.09; 95% confidence interval [CI], 1.02-1.16) and diabetes (AHR: 1.33; 95% CI, 1.27-1.39). Risks of MI and diabetes were similarly increased among men with and without specific comorbid illnesses (p>0.10 for all interactions, with one exception). Previous MI, congestive heart failure, peripheral arterial disease, stroke, hypertension, chronic obstructive pulmonary disease, and renal disease were associated with new MI and diabetes, and obesity and rheumatologic disease were also associated with diabetes. Limitations include the observational study design, reliance on administrative data to ascertain outcomes, and lack of information on risk factors such as smoking and family history.
conclusionsTraditional risk factors for MI and diabetes were also associated with developing these conditions during ADT but did not significantly modify the risk attributable to ADT. Strategies to screen and prevent diabetes and cardiovascular disease in men with PCa should be similar to the strategies recommended for the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.